Swimming champion Cate Campbell spearheads national campaign to save lives from melanoma
5 February 2019
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Cate today joined MIA Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, and CEO Matthew Browne on a tour of Melanoma Institute Australia in Sydney. Cate also met young mum Jenny Day and her three little girls who lost their dad and husband David to melanoma. They are one of four families bravely sharing their stories of loss for the 2019 Melanoma March campaign.
Melanoma Institute Australia CEO Matthew Browne says the organisation is delighted to have Cate Campbell onboard as the 26-year-old athlete’s own recent brush with melanoma compellingly demonstrates the importance of being sun-safe and aware of changes to your skin.
Cate embodies the Australian way of life and her love of the outdoors, be it swimming, hiking or kayaking, makes her an ideal National Ambassador for MIA,” Matthew said. “Many people don’t realise melanoma kills one Australian every five hours and is the most common cancer affecting 15 to 39 year olds. By having Cate onboard we will better be able to reach young Australians with sun-safety and skin awareness messages.
Cate went for a skin check in November 2018 after bumping into a friend who had a near miss with melanoma. Cate had a mole on her arm removed during the check, which turned out to be Stage I melanoma and required further surgery. It was her melanoma diagnosis that inspired her to become an advocate for the importance of sun safety and skin checks.
As Australians, we spend so much time in the sun and with melanoma the most common cancer in young Australians I want to make sure people know the importance of having skin checks,” said Cate. “As someone with pale, freckly skin, keeping up with freckles and sun spots is difficult, but my melanoma developed in a mole I had my whole life and on the surface it looked like nothing had changed. I shudder to think what would have happened had I not had that mole checked. It literally saved my life.”
Melanoma Institute Australia is leading global research efforts to find a cure for melanoma. Despite recent breakthroughs tripling life expectancy for many advanced melanoma patients, more research is needed into why some people just don’t respond, and also to determine how to tackle earlier stage disease.
To reach zero deaths from melanoma, we need to crack the riddle of so-called ‘super progressors’, like David Day, whose disease progresses rapidly despite these new treatments and they die within months” said Professor Georgina Long. “We also need to better understand how we can use these new treatments during earlier stage melanoma, to stop it spreading to vital organs in the first place,” added Professor Scolyer. Melanoma March raises money to enable such national collaborative research projects to find a cure for melanoma. This year there will be 23 family friendly Melanoma March events across the country, as well as the 2000km Jay’s Longest Melanoma March from Adelaide to Sydney.
"I will be joining the Melanoma March event in my home town of Brisbane as I know I was incredibly lucky, but for so many people diagnosed with melanoma this isn’t the case,” Cate said.
We need to keep encouraging Australians to prioritise sun safety and skin awareness as part of their health regime, and we need answers. To find those answers we need research, and that means raising much-needed research dollars through campaigns like Melanoma March.
Please join me in helping those Australians bravely battling for their lives, and supporting families like David Day’s who are left behind.”
For more information on how to register for a march near you or donate to Melanoma March, go to www.melanomamarch.org.au
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?